Cargando…
Grapiprant: A snapshot of the current knowledge
Grapiprant is the pioneer member of the novel piprant class, a potent and specific antagonist of the prostaglandin E2 receptor 4. It has been approved in veterinary medicine for the control of pain and inflammation associated with osteoarthritis in dogs at the dose regimen of 2 mg/kg once a day by t...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518515/ https://www.ncbi.nlm.nih.gov/pubmed/34057218 http://dx.doi.org/10.1111/jvp.12983 |
_version_ | 1784584242140807168 |
---|---|
author | Sartini, Irene Giorgi, Mario |
author_facet | Sartini, Irene Giorgi, Mario |
author_sort | Sartini, Irene |
collection | PubMed |
description | Grapiprant is the pioneer member of the novel piprant class, a potent and specific antagonist of the prostaglandin E2 receptor 4. It has been approved in veterinary medicine for the control of pain and inflammation associated with osteoarthritis in dogs at the dose regimen of 2 mg/kg once a day by the FDA and EMA (for pain only) in 2016 and 2018, respectively. The aim of this narrative review was to report the analytical methods, pharmacokinetics, pharmacodynamics and safety of grapiprant in several animal species using the best available published scientific evidence. In conclusion, most of the analytical methods proposed for grapiprant detection are simple, reliable, sensitive and validated. The pharmacokinetics show discrepancies between animal species. The therapeutic efficacy seems more suited to chronic rather than acute pain. |
format | Online Article Text |
id | pubmed-8518515 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85185152021-10-21 Grapiprant: A snapshot of the current knowledge Sartini, Irene Giorgi, Mario J Vet Pharmacol Ther Review Articles Grapiprant is the pioneer member of the novel piprant class, a potent and specific antagonist of the prostaglandin E2 receptor 4. It has been approved in veterinary medicine for the control of pain and inflammation associated with osteoarthritis in dogs at the dose regimen of 2 mg/kg once a day by the FDA and EMA (for pain only) in 2016 and 2018, respectively. The aim of this narrative review was to report the analytical methods, pharmacokinetics, pharmacodynamics and safety of grapiprant in several animal species using the best available published scientific evidence. In conclusion, most of the analytical methods proposed for grapiprant detection are simple, reliable, sensitive and validated. The pharmacokinetics show discrepancies between animal species. The therapeutic efficacy seems more suited to chronic rather than acute pain. John Wiley and Sons Inc. 2021-05-31 2021-09 /pmc/articles/PMC8518515/ /pubmed/34057218 http://dx.doi.org/10.1111/jvp.12983 Text en © 2021 The Authors. Journal of Veterinary Pharmacology and Therapeutics published by John Wiley & Sons Ltd https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Articles Sartini, Irene Giorgi, Mario Grapiprant: A snapshot of the current knowledge |
title | Grapiprant: A snapshot of the current knowledge |
title_full | Grapiprant: A snapshot of the current knowledge |
title_fullStr | Grapiprant: A snapshot of the current knowledge |
title_full_unstemmed | Grapiprant: A snapshot of the current knowledge |
title_short | Grapiprant: A snapshot of the current knowledge |
title_sort | grapiprant: a snapshot of the current knowledge |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518515/ https://www.ncbi.nlm.nih.gov/pubmed/34057218 http://dx.doi.org/10.1111/jvp.12983 |
work_keys_str_mv | AT sartiniirene grapiprantasnapshotofthecurrentknowledge AT giorgimario grapiprantasnapshotofthecurrentknowledge |